New findings from the open-label SPLASH trial show patients with mCRPC achieved improved progression-free survival as well as response rates and antigen-specific reductions. Prostate-specific membrane ...

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01). Serum glycoproteins involved in complement cascade and lipid metabolism ...

Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm. The combination of enzalutamide (Xtandi) plus radium-223 (Ra223, Xofigo) for the treatment of metastatic ...

“Today, we're presenting the results of this analysis, and we show that patients who have a high Decipher score derive significant benefit from docetaxel,” says Gerhardt Attard, MD, PhD, FRCP. In this ...

“I think that these data in this approximately 700 patient trial consolidates and makes a strong case for the role of pembrolizumab in the adjuvant setting,” says Guru P. Sonpavde, MD. In this video, ...

According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001). Results of the phase 3 ARANOTE study ...

Investigators observed promising clinical effect with the EGFR / HER3 bispecific antibody-drug conjugate. Epidermal growth factor receptor (EGFR) / epidermal growth factor 3 (HER3) bispecific antibody ...

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD. Results of a large phase 3 study support the use of ...

Radium223 (Xofigo), a calcium mimetic radioactive therapy indicated to treat prostate cancer, may be a particularly beneficial symptom-treating therapy as a regimen prior to chemotherapy in patients ...

"I think it's going to help younger or less experienced urologists get more proficient at this procedure faster. That's where the AI is going to come into play," says Lewis S. Kriteman, MD, FACS. In ...

Panelists discuss how the dosing and administration of different abiraterone formulations vary, how food-related effects impact treatment efficacy, and strategies to manage these effects for optimal ...

mCRPC patients? How do you navigate these challenges to ensure patients receive optimal care? How might the barriers differ between various health care settings (eg, rural vs urban, private vs public) ...